VSIG-3/IGSF11 silencing in A2058 melanoma cells simultaneously suppresses melanoma progression and induces anti-tumoral cytokine profile in human T cells: In silico and in vitro study

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 4, 2024

Language: Английский

Novel Peptide-Based ⁶⁸Ga-Labeled Radiotracer for Preclinical Studies of TIM3 Expression

Molecular Pharmaceutics, Journal Year: 2024, Volume and Issue: 22(1), P. 270 - 283

Published: Nov. 8, 2024

T-cell immunoglobulin and mucin domain-3 (TIM3) is an immune checkpoint that plays a negative regulatory role in the response. TIM3-targeted drugs inhibit this regulation, thereby modulating level of response activation. In previous investigation, several peptides targeting TIM3 were identified through screening from phage peptide library. research, three selected to construct radioactive molecular probes according characteristic would lead increase interferon-γ (IFN-γ) secretion. Molecular docking was performed assess binding properties with protein. To further enhance properties, one higher-affinity structurally modified. Then,

Language: Английский

Elevated Galectin-3 levels in the tumor microenvironment of ovarian cancer – implication of ROS mediated suppression of NK cell antitumor response via tumor-associated neutrophils

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Dec. 20, 2024

Ovarian cancer is a lethal disease with low survival rates for women diagnosed in advanced stages. Current immunotherapies are not efficient ovarian cancer, and there therefore significant need novel treatment options. The β-galactoside-binding lectin, Galectin-3, involved different immune processes has been associated poor outcome various diagnoses. Here, we investigated how Galectin-3 affects the interaction between natural killer (NK) cells neutrophils tumor microenvironment of cancer.

Language: Английский